Get the Stockscreener App
89.73
1.62%
1.43
Pre-market:
91.62
1.89
+2.11%
Glaukos Corporation stock is traded at $89.73, with a volume of 512.02K.
It is up +1.62% in the last 24 hours and down -12.25% over the past month.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
See More
Previous Close:
$88.30
Open:
$89.81
24h Volume:
512.02K
Relative Volume:
0.57
Market Cap:
$5.40B
Revenue:
$360.35M
Net Income/Loss:
$-149.57M
P/E Ratio:
-30.31
EPS:
-2.96
Net Cash Flow:
$-81.27M
1W Performance:
-5.07%
1M Performance:
-12.25%
6M Performance:
-31.86%
1Y Performance:
-9.32%
1-Day Range:
$88.14
$90.50
1-Week Range:
$86.16
$92.98
52-Week Range:
$77.91
$163.71
Glaukos Corporation Stock (GKOS) Company Profile
Name
Glaukos Corporation
Sector
Industry
Phone
949-367-9600
Address
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
89.73 | 5.40B | 360.35M | -149.57M | -81.27M | -2.96 |
|
ABT
Abbott Laboratories
|
131.73 | 218.91B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.05 | 139.37B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
348.12 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
83.37 | 106.90B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.60 | 41.45B | 5.72B | 4.17B | 259.90M | 6.97 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-25 | Upgrade | Mizuho | Neutral → Outperform |
| Dec-11-24 | Upgrade | Citigroup | Neutral → Buy |
| Dec-06-24 | Initiated | UBS | Buy |
| Dec-02-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-10-24 | Downgrade | Citigroup | Buy → Neutral |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-21-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-04-23 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-28-23 | Initiated | Truist | Buy |
| Nov-08-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-07-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-19-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Oct-04-22 | Initiated | Needham | Buy |
| Jul-12-22 | Upgrade | Stifel | Hold → Buy |
| Feb-03-22 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-19-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jan-18-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-03-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Jul-26-21 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jul-20-21 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jul-14-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-08-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Upgrade | Citigroup | Sell → Neutral |
| Dec-09-20 | Initiated | Oppenheimer | Perform |
| Nov-17-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-08-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-15-20 | Initiated | Jefferies | Hold |
| Mar-05-20 | Initiated | Citigroup | Sell |
| Feb-28-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-20 | Upgrade | Berenberg | Hold → Buy |
| Dec-12-19 | Downgrade | Wells Fargo | Outperform → Underperform |
| Sep-30-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Mar-08-19 | Initiated | BTIG Research | Neutral |
| Aug-30-18 | Initiated | Berenberg | Hold |
| Aug-29-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-03-18 | Reiterated | Stifel | Hold |
| Jun-21-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-13-18 | Downgrade | Stifel | Buy → Hold |
| Mar-01-18 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-02-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-06-17 | Upgrade | Stifel | Hold → Buy |
| Oct-27-16 | Initiated | Wells Fargo | Outperform |
View All
Glaukos Corporation Stock (GKOS) Latest News
Gel Stent Market Size, Share & Trends Analysis Report 2025-2032 | Allergan, Alcon, Innfocus and Glaukos Corp. - openPR.com
Glaukos Buys OC Office for $16.6M - Orange County Business Journal
First Week of June 20th Options Trading For Glaukos (GKOS) - Nasdaq
Glaukos Announces the Release of its 2024 Sustainability Report - GuruFocus
Lobbying Update: $45,000 of GLAUKOS CORPORATION lobbying was just disclosed - Nasdaq
Forecasting The Future: 7 Analyst Projections For Glaukos - Benzinga
(GKOS) Long Term Investment Analysis - news.stocktradersdaily.com
Stifel cuts Glaukos stock target to $140, maintains buy rating - Investing.com Australia
Stifel cuts Glaukos stock target to $140, maintains buy rating By Investing.com - Investing.com Canada
Glaukos (GKOS) Price Target Reduced by Stifel Amid Flat iDose Volumes | GKOS Stock News - GuruFocus
Glaukos (GKOS) Price Target Reduced by Mizuho Amid Q1 Outlook | GKOS Stock News - GuruFocus
Piper Sandler cuts Glaukos stock price target to $165 By Investing.com - Investing.com Canada
AVEDRO, INC. SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces an Investigation of Avedro, Inc. (AVDR) Over the Proposed Merger of the Company with Glaukos Corporation - marketscreener.com
Piper Sandler cuts Glaukos stock price target to $165 - Investing.com
Piper Sandler Adjusts Glaukos (GKOS) Price Target Amid Stock Dec - GuruFocus
Glaukos (GKOS) Sees Price Target Reduction as MedTech Sector Fac - GuruFocus
Truist Adjusts Price Target for Glaukos (GKOS) Ahead of Q1 Repor - GuruFocus
Glaukos price target lowered to $140 from $185 at Truist - TipRanks
Figure 1. iStent inject GTS 400 (Glaukos Corporation, San Clemente, CA)... - ResearchGate
Keratoconus Therapeutics Market Size in 7MM is expected to grow - openPR.com
Gel Stent Market Generated Opportunities, Future Scope 2025-2032 | Allergan, Alcon, Innfocus and Glaukos Corp. - openPR.com
Glaukos to Release First Quarter 2025 Financial Results after Ma - GuruFocus
Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30 - BioSpace
What Makes Glaukos Corporation (GKOS) a Compelling Stock? - Insider Monkey
Glaukos: Macro Environment & Limited Market Access Could Stunt Growth Plans (NYSE:GKOS) - Seeking Alpha
Glaukos stock plunge confirms InvestingPro’s February overvaluation warning By Investing.com - Investing.com Australia
Glaukos stock touches 52-week low at $91.65 amid market shifts By Investing.com - Investing.com South Africa
Glaukos stock touches 52-week low at $91.65 amid market shifts - Investing.com Australia
Glaukos Corp (GKOS) Stock Price Up 2.95% on Apr 2 - GuruFocus
The Zacks Analyst Blog Highlights Alcon, Glaukos and Regeneron Pharmaceuticals - Yahoo Finance
Learn to Evaluate (GKOS) using the Charts - news.stocktradersdaily.com
Glaukos CFO Thurman Alex R. sells $162k in stock By Investing.com - Investing.com South Africa
Glaukos CFO Thurman Alex R. sells $162k in stock - Investing.com India
Glaukos Corporation (NYSE:GKOS) Is Expected To Breakeven In The Near Future - simplywall.st
Breakeven On The Horizon For Glaukos Corporation (NYSE:GKOS) - Yahoo Finance
Primecap Management Co. CA Has $182.08 Million Position in Glaukos Co. (NYSE:GKOS) - MarketBeat
First Week of May 16th Options Trading For Glaukos (GKOS) - Nasdaq
(GKOS) Trading Report - Stock Traders Daily
Glaukos, RadiusXR, and Topcon Healthcare Work to Advance Vision Testing - Medical Product Outsourcing
RadiusXR and Glaukos Announce a New Collaboration With Topcon Healthcare, Inc., and the Launch of Inspire - Vision Monday
Here's Why You Should Retain Glaukos Stock in Your Portfolio - MSN
Glaukos Corporation Stock (GKOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):